Terms: = Leukemia AND BAP1, DKFZp686N04275, 8314, ENSG00000163930, Q92560, KIAA0272, hucep-6, HUCEP-13, FLJ37180, FLJ35406 AND Prognosis
6 results:
1. Epigenetic targeted therapy of stabilized bap1 in ASXL1 gain-of-function mutated leukemia.
Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
[TBL] [Abstract] [Full Text] [Related]
2. Gene Expression Analysis of Pediatric Acute Myeloid leukemia Identified a Hyperactive ASXL1/bap1 Axis Linked with Poor prognosis and over Expressed Epigenetic Modifiers.
Elyamany G; Akhter A; Kamran H; Rizwan H; Shabani-Rad MT; Alkhayat N; Al Sharif O; Elborai Y; Al Shahrani M; Mansoor A
Pediatr Hematol Oncol; 2021 Sep; 38(6):581-592. PubMed ID: 33764257
[TBL] [Abstract] [Full Text] [Related]
3. Tumor-derived neomorphic mutations in ASXL1 impairs the bap1-ASXL1-FOXK1/K2 transcription network.
Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
[TBL] [Abstract] [Full Text] [Related]
4. [Molecular mechanisms by which the mutant ASXL1/bap1 complex aggravates myeloid leukemia].
Asada S
Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
[TBL] [Abstract] [Full Text] [Related]
5. Mutant ASXL1 cooperates with bap1 to promote myeloid leukaemogenesis.
Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
[TBL] [Abstract] [Full Text] [Related]
6. Functional and cancer genomics of ASXL family members.
Katoh M
Br J Cancer; 2013 Jul; 109(2):299-306. PubMed ID: 23736028
[TBL] [Abstract] [Full Text] [Related]
